In a preceding publication,1 it was shown that when 80 subjects with normal eyes were subjected to topical application of 0.1% dexamethasone 21-phosphate three times daily for four weeks, three levels of ocular hypertensive response became apparent: low, which consisted of an applanation pressure rise not exceeding 5 mm Hg and included 53 subjects (group 1); intermediate, which consisted of a pressure rise of 6 to 15 mm Hg and included 23 subjects (group 2A); and high, which consisted of a pressure rise greater than 15 mm Hg and included four subjects (group 2B). It was shown further that in addition to differences in absolute magnitude of response, qualitative differences could be demonstrated among these different groups, ie, the pressure rise in the group with the low level of response reached maximum after two weeks of drug application, whereas it continued to increase throughout the four-week period in the
ARMALY MF. Dexamethasone Ocular Hypertension in the Clinically Normal Eye: II. The Untreated Eye, Outflow Facility, and Concentration. Arch Ophthalmol. 1966;75(6):776–782. doi:https://doi.org/10.1001/archopht.1966.00970050778013
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: